(Q36014340)

11 August 2017

1 reference

title

Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan (English)

1 reference

11 August 2017

main subject

cardiovascular disease

1 reference

S G Chrysant

1

1 reference

11 August 2017

G S Chrysant

series ordinal

2

1 reference

11 August 2017

A Desai

series ordinal

3

1 reference

11 August 2017

publication date

1 March 2005

1 reference

Journal of Human Hypertension

11 August 2017

published in

1 reference

11 August 2017

volume

19

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

173-183

1 reference

Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Vascular remodeling: the role of angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Circadian rhythms and clinical medicine with applications to hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) i

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Angiotensin receptor blockers: how important is selectivity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3', 5'-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Regression of media-to-lumen ratio of human subcutaneous arteries and left ventricular hypertrophy during treatment with an angiotensin-converting enzyme inhibitor-based regimen in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Renoprotection by angiotensin-receptor blockers and ACE inhibitors in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Workshop: endothelial cell dysfunction leading to diabetic nephropathy : focus on nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Telmisartan: a review of its use in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Racial differences in pressure, volume and renin interrelationships in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

Blood pressure and end-stage renal disease in men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Cyclic and circadian variations in cardiovascular events

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Circadian variation of plaque rupture in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Effects of Eprosartan Versus Enalapril in Hypertensive Patients on the Renin-Angiotensin-Aldosterone System and Safety Parameters: Results from a 26-Week, Double-blind, Multicentre Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Chymase-dependent angiotensin II formation in human vascular tissue

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Pharmacology of AT1-receptor blockers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Diabetic nephropathy: can renoprotection be extrapolated to cardiovascular protection?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001808

7 January 2021

Identifiers

DOI

10.1038/SJ.JHH.1001808

1 reference

11 August 2017

1 reference